Clinical Trials Browser

Phase 2/3 × Carcinoma, Squamous Cell × Erlotinib Hydrochloride × Clear all

NCT00448240 2025-03-18

Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer

Phase 2/3 Terminated

6 enrolled 4 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms